Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease. uri icon

authors

  • Jessen, Frank
  • De Deyn, Peter Paul
  • Düzel, Emrah
  • Engelborghs, Sebastiaan
  • Ewers, Michael
  • Exalto, Lieza G
  • van der Flier, Wiesje M
  • Fortea, Juan
  • Frederiksen, Kristian Steen
  • Frisoni, Giovanni B
  • Frölich, Lutz
  • Arbizu, Javier
  • Garza-Martinez, Alejandro J
  • Grimmer, Timo
  • Hanseeuw, Bernard
  • Hort, Jakub
  • Ivanoiu, Adrian
  • Kehoe, Patrick G
  • Kennelly, Sean P
  • Kern, Silke
  • Klöppel, Stefan
  • Krajčovičová, Lenka
  • Boada, Mercé
  • Kramberger, Milica G
  • Bernadette McGuinness, MD, PhD
  • Mecocci, Patrizia
  • Oberstein, Timo Jan
  • Ousset, Pierre-Jean
  • Paquet, Claire
  • Perneczky, Robert
  • Piazza, Fabrizio
  • Plantone, Domenico
  • Rainero, Innocenzo
  • Balasa, Mircea
  • Sacco, Guillaume
  • Salmon, Eric
  • Santana, Isabel
  • Scarmeas, Nikolaos
  • Schneider, Anja
  • Schott, Jonathan M
  • Solje, Eino
  • Stefanova, Elka
  • Stögmann, Elisabeth
  • Strauss, Mélanie
  • Bennys, Karim
  • Sutovsky, Stanislav
  • Waldemar, Gunhild
  • Winblad, Bengt
  • Boban, Marina
  • Bürger, Katharina
  • Chincarini, Andrea
  • Cagnin, Annachiara

publication date

  • July 9, 2025